Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, announced a “significant milestone” in its development of treatments for androgenetic alopecia, or hair loss: the granting of a second U.S. patent issued for JW-700, a topical treatment designed to improve minoxidil’s efficacy. The patent was issued by the U.S. Patent and Trademark Office. The patent adds to the growing global intellectual property (“IP”) estate for Safety Shots Legacy products. According to the announcement, minoxidil is a common treatment of hair loss sold under brand names including Rogaine(R) and Hair Regrowth for Men(R), and Safety Shot’s JW-700 has been shown to increase key enzymes needed for minoxidil to work by up to seven times over a two-week period. The company has launched the product in India, where it is exceeding sales projections, and is planning product expansion into 30 more countries through a distribution partnership with Cosmofix & San Pellegrino.
“This new, broader U.S. patent, encompassing new formulations, is a crucial component of Safety Shot’s ongoing pursuit of the $1.5 billion minoxidil hair loss market,” said Safety Shot CEO Brian John in the press release. “Following its launch in India in July of 2023, sales of MinoxiBoost have exceeded all expectations and we expect our distribution partners will continue to deliver robust sales. The recently completed clinical trial is a vital next step to support a full launch of JW-700 in the U.S. and other key markets. We look forward to reporting data in the coming weeks as well as the launch of this incredible product in the USA.”
To view the full press release, visit https://ibn.fm/cyCxb
About Safety Shot
Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. The company plans to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders. For more information about the company, visit www.SafetyShotHoldings.com.
NOTE TO INVESTORS: The latest news and updates relating to SHOT are available in the company’s newsroom at https://ibn.fm/SHOT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN